NEW YORK, June 17, 2016 /PRNewswire/ -- CBL & Associates Properties, Inc. (CBL)
Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
Eagle Pharmaceuticals, Inc. (EGRX)
Lifshitz & Miller announces investigation on behalf of EGRX investors. Specifically, on March 18, 2016, EGRX announced receipt of a CRL from the FDA, regarding Kangio, disapproving the drug application in its current form and requested additional information regarding the substance used in Kangio.
HCP, Inc. (HCP)
Lifshitz & Miller announces investigation on behalf of HCP investors. Specifically, on February 9, 2016, HCP disclosed that its equity stake in ManorCare had been written down to zero, and that it had taken an $836 million non-cash impairment on its ManorCare lease assets and placed all of its ManorCare real estate assets on a "Watch List."
Immunomedics, Inc. (IMMU)
Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by Immunomedics board. Specifically, the investigation relates to whether Immunomedics misrepresented to ASCO that its abstract for IMMU-132 contained only updated and previously undisclosed data in violation of ASCO's policy.
Infinity Pharmaceuticals Inc. (INFI)
Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the INFI board. Specifically, on June 14, 2016, INFI announced a restructuring that would reduce its workforce by 21% in the wake of disappointing drug-study results.
Neovasc, Inc. (NVCN)
Lifshitz & Miller announces investigation on behalf of Neovasc investors. Specifically, the investigation will focus on multiple media reports that claim a Massachusetts federal jury awarded a $70 million verdict to Neovasc's rival, CardiAQ Valve Technologies Inc. ("CardiAQ"), finding that Neovasc had stolen trade secrets from CardiAQ.
Unilife Corporation (UNIS)
Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by UNIS board. Specifically, the investigation relates to whether Unilife's former CEO and its former Chairman had violated Company policies and broken laws and regulations; and Unilife lacked sufficient accounting and financial reporting internal controls.
ATTORNEY ADVERTISING. © 2016 Lifshitz & Miller. The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Joshua M. Lifshitz, Esq.
Lifshitz & Miller
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lifshitz--miller-law-firm-announces-investigation-of-cbl--associates-properties-inc-eagle-pharmaceuticals-inc-hcp-inc-immunomedics-inc-infinity-pharmaceuticals-inc-neovasc-inc-and-unilife-corporation-300286669.html
SOURCE Lifshitz & Miller Law Firm